青藤碱与表柔比星联合处理对黑色素瘤细胞侵袭相关蛋白变化的影响

doi:10.3969/j.issn.1006-6233.2018.12.018

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (1690 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the effect of sinomenine (SIN) combined with epirubicin (EPI) on the changes of invasion-related proteins in melanoma cells. Methods: The invasion status of melanoma A375 cells under different conditions was detected by Transwell. They were divided into control group (given normal saline), SIN group (10 g/mL, 100 g/mL as low concentration and high concentration), EPI group (5 g/mL, 50 g/mL as low concentration and high concentration), SIN+EPI group (10 g/mL, 5 g/mL) and SIN+EPI group (5 g/mL). The expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) proteins and their mRNA were detected by RT-PCR and Western blot. Results: The inhibition rate of SIN+EPI group on the invasion of melanoma A375 cells was significantly higher than that in group SIN and EPI (P<0.05). Moreover, with the increase of SIN and EPI concentration, the inhibition of SIN and EPI on the invasion of A375 cells increased significantly. Compared with the control group, the levels of MMP-2, MMP-9 protein and mRNA in SIN group, the EPI group and the SIN+EPI group were inhibited in varying degrees. Among them, the inhibition effect of SIN+EPI group was higher (P<0.05). Conclusion: The use of low concentration (10μg/mL) SIN can effectively promote the inhibitory effect of low concentration of EPI on the invasion of melanoma cells, and SIN can be used as an important drug for adjuvant chemotherapy. It can play a role in improving the clinical efficacy. SIN combined with EPI chemotherapy drugs can play a synergistic and synergistic effect, and can reduce the dosage of EPI, in order to prevent a series of toxic and side effects caused by high concentration of chemotherapeutic drugs, so it has good safety and effectiveness.

Key words： Melanoma Epirubicin Sinomenine A375 cell Matrix metalloproteinases

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.12.018 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I12/2009

[1] Forsyth PA, Smalley KSM, Sondak VK. BRAF-MEK inhibition in melanoma brain metastases: a new hope[J]. Lancet Oncol, 2017, 18(7): 836~837.
[2] 万荔,孙同文,秦贵军,等.腰椎脊膜恶性黑色素瘤一例[J].郑州大学学报(医学版),2017,52(2):235~236.
[3] 吴星,袁定芬.黑色素瘤干细胞标志物研究及其相关治疗:认识与针对性[J].中国组织工程研究,2018,22(1):152~157.
[4] 阿克拜尔·苏来曼,阿米娜·亚合甫,万学峰,等.恶性黑色素瘤患者术后预后评价及预后因素分析[J].河北医学,2016,22(5):785~788.
[5] Imredi E, Plotar V, Szavcsur P, et al. Treatment of metastatic progression following the synchronous occurrence of cutaneous and ocular primary melanomas[J]. Orv Hetil, 2018, 159(16): 642~647.
[6] Parmiani G. Melanoma cancer stem cells: markers and functions[J]. Cancers, 2016, 8(3): 34.
[7] Thomas S, Aggarwal R, Jahan T, et al. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma[J]. Ann Oncol, 2016, 27(5): 947~952.
[8] Cecchini S, Sarti D, Ricci S, et al. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma[J]. World Clin Oncol, 2015, 6(4): 57.
[9] Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects[J]. Br Ophthalmol, 2017, 101(1): 38~44. .
[10] 易恒安.皮肤恶性黑色素瘤临床病理分析探究[J].河北医学,2013,19(7):1078~1080.
[11] 孙越华,朱清,李俊旭,等.青藤碱抗炎免疫与抗肿瘤作用研究新进展[J].中国药理学通报,2015,31(8):1040~1043.
[12] 陈淑瑜,邹勇,黄轶群,等.盐酸青藤碱对Jeko-1细胞增殖、凋亡的影响及其作用机制研究[J].中国实验血液学杂志,2017,25(6):1675~1679.
[13] Bird J, Danson S, Nolan M. Melanoma, riding the rollercoaster: a longitudinal Grounded Theory study of the experiences of melanoma patients and their carers[J]. Eur Cancer, 2017, 72(1): S169~S170.
[14] 刘端,李红雨,臧星卉,等.VEGF、MMP-9在卵巢癌组织中的表达及贝伐单抗联合顺铂对卵巢癌细胞SKOV3的作用[J].郑州大学学报(医学版),2018,53(4):516~520.